In 2011, Yang et al. studied the bioactivity in vitro and in vivo of lipid–PEI2000–DNA (sLPD) nanoparticles conjugated with a phosphorothioate ASO (G3139), designed for Bcl-2 downregulation in cancer cells [112]. Here, BCL2 is linked to cancer.